South Korea · Delayed Price · Currency is KRW Hanmi Pharm. Statistics
Total Valuation
Hanmi Pharm. has a market cap or net worth of KRW 4.04 trillion. The enterprise value is 4.45 trillion.
| Market Cap | 4.04T |
| Enterprise Value | 4.45T |
Important Dates
The next estimated earnings date is Wednesday, October 29, 2025.
| Earnings Date | Oct 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Hanmi Pharm. has 12.68 million shares outstanding. The number of shares has decreased by -0.05% in one year.
| Current Share Class | 12.68M |
| Shares Outstanding | 12.68M |
| Shares Change (YoY) | -0.05% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 7.81% |
| Owned by Institutions (%) | 19.74% |
| Float | 6.20M |
Valuation Ratios
The trailing PE ratio is 37.68 and the forward PE ratio is 23.82. Hanmi Pharm.'s PEG ratio is 1.45.
| PE Ratio | 37.68 |
| Forward PE | 23.82 |
| PS Ratio | 2.76 |
| PB Ratio | 3.16 |
| P/TBV Ratio | 3.73 |
| P/FCF Ratio | 36.97 |
| P/OCF Ratio | 26.73 |
| PEG Ratio | 1.45 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.22, with an EV/FCF ratio of 40.65.
| EV / Earnings | 41.44 |
| EV / Sales | 3.03 |
| EV / EBITDA | 15.22 |
| EV / EBIT | 22.86 |
| EV / FCF | 40.65 |
Financial Position
The company has a current ratio of 1.24, with a Debt / Equity ratio of 0.34.
| Current Ratio | 1.24 |
| Quick Ratio | 0.72 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | 1.51 |
| Debt / FCF | 4.02 |
| Interest Coverage | 9.35 |
Financial Efficiency
Return on equity (ROE) is 9.43% and return on invested capital (ROIC) is 7.03%.
| Return on Equity (ROE) | 9.43% |
| Return on Assets (ROA) | 6.18% |
| Return on Invested Capital (ROIC) | 7.03% |
| Return on Capital Employed (ROCE) | 14.24% |
| Revenue Per Employee | 625.65M |
| Profits Per Employee | 45.82M |
| Employee Count | 2,343 |
| Asset Turnover | 0.74 |
| Inventory Turnover | 2.27 |
Taxes
In the past 12 months, Hanmi Pharm. has paid 27.19 billion in taxes.
| Income Tax | 27.19B |
| Effective Tax Rate | 18.75% |
Stock Price Statistics
The stock price has increased by +0.62% in the last 52 weeks. The beta is 0.61, so Hanmi Pharm.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.61 |
| 52-Week Price Change | +0.62% |
| 50-Day Moving Average | 289,120.00 |
| 200-Day Moving Average | 271,692.50 |
| Relative Strength Index (RSI) | 69.71 |
| Average Volume (20 Days) | 73,310 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Hanmi Pharm. had revenue of KRW 1.47 trillion and earned 107.35 billion in profits. Earnings per share was 8,465.57.
| Revenue | 1.47T |
| Gross Profit | 802.20B |
| Operating Income | 194.61B |
| Pretax Income | 145.03B |
| Net Income | 107.35B |
| EBITDA | 292.34B |
| EBIT | 194.61B |
| Earnings Per Share (EPS) | 8,465.57 |
Balance Sheet
The company has 188.04 billion in cash and 440.19 billion in debt, giving a net cash position of -252.15 billion or -19,885.22 per share.
| Cash & Cash Equivalents | 188.04B |
| Total Debt | 440.19B |
| Net Cash | -252.15B |
| Net Cash Per Share | -19,885.22 |
| Equity (Book Value) | 1.28T |
| Book Value Per Share | 89,001.43 |
| Working Capital | 140.45B |
Cash Flow
In the last 12 months, operating cash flow was 151.33 billion and capital expenditures -41.90 billion, giving a free cash flow of 109.42 billion.
| Operating Cash Flow | 151.33B |
| Capital Expenditures | -41.90B |
| Free Cash Flow | 109.42B |
| FCF Per Share | 8,629.37 |
Margins
Gross margin is 54.72%, with operating and profit margins of 13.28% and 7.32%.
| Gross Margin | 54.72% |
| Operating Margin | 13.28% |
| Pretax Margin | 9.89% |
| Profit Margin | 7.32% |
| EBITDA Margin | 19.94% |
| EBIT Margin | 13.28% |
| FCF Margin | 7.46% |
Dividends & Yields
This stock pays an annual dividend of 1,250.00, which amounts to a dividend yield of 0.42%.
| Dividend Per Share | 1,250.00 |
| Dividend Yield | 0.42% |
| Dividend Growth (YoY) | 150.00% |
| Years of Dividend Growth | 7 |
| Payout Ratio | 34.58% |
| Buyback Yield | 0.05% |
| Shareholder Yield | 0.46% |
| Earnings Yield | 2.65% |
| FCF Yield | 2.71% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 27, 2023. It was a forward split with a ratio of 1.02.
| Last Split Date | Dec 27, 2023 |
| Split Type | Forward |
| Split Ratio | 1.02 |
Scores
Hanmi Pharm. has an Altman Z-Score of 4.84 and a Piotroski F-Score of 5.
| Altman Z-Score | 4.84 |
| Piotroski F-Score | 5 |